STIFEL 2026 HEALTHCARE CONFERENCE - 4D MOLECULAR THERAPEUTICS INC

Financial Performance:

• No specific revenue, earnings, or profit margin figures provided; company is pre-commercial stage with a single product candidate in clinical development.
• Financial position described as "strong" with a cash runway projected to extend into the second half of 2028.
• Reimbursement strategy relies on the "buy-and-bill" model familiar to retina clinics, expecting a single upfront reimbursement event higher than current per-dose anti-VEGF prices to compensate for reduced treatment frequency.
• Economic model aims to capture value from the 60% of patients who typically discontinue therapy within five years under current paradigms, alongside addressing clinic capacity constraints where 40% of providers report full schedules.

Guidance and Future Outlook:

• Phase 3 trials (Forefront I and Forefront II) are fully enrolled with top-line readouts scheduled for Q2 2027 (Forefront I) and the second half of 2027 (Forefront II).
• Primary endpoint for Phase 3 is non-inferiority in visual acuity (difference of approx. 4 letters) at Week 52 compared to labeled aflibercept.
• Long-term goal is to establish 4D-150 as a "backbone therapy" providing lifelong, continuous disease control from a single injection, potentially rendering the disease "injection-free" for a significant portion of patients.
• Management expects broad commercial adoption driven by the alignment of unmet needs for patients, physicians, and payers.

Business Segments and Product Lines:

• Primary focus is on lead program 4D-150, a gene therapy for wet age-related macular degeneration (wet AMD).
• Technology utilizes the proprietary R100 capsid vector for low-dose, targeted intravitreal delivery of the aflibercept (VEGF) transgene.
• Phase 2 PRISM trial data in recently diagnosed patients showed:
  • 87% reduction in treatment burden over two years compared to quarterly aflibercept.
  • 66% of patients achieved injection-free status by the two-year mark.
  • Sustained anatomical control (central subfield thickness) and visual acuity maintenance.
  • Average of 1.6 supplemental injections required over two years for the cohort.
• Safety profile in Phase 3 dose cohorts (71 patients) showed no serious adverse events (e.g., retinal vasculitis, endophthalmitis); early inflammation cases were mild, transient, and resolved with a 20-week prophylactic steroid regimen (Durazol).

Market and Competitive Landscape:

• Wet AMD is a $16 billion market characterized by a chronic, heterogeneous disease course and significant unmet need for continuous disease control to prevent vision loss between bolus injections.
• Key differentiator against competitors: 4D-150 is intravitreal (clinic-based injection) versus subretinal (surgical) approaches like RegenXBIO's program.
• Differentiation from other intravitreal gene therapies (e.g., Adverum/Lilly) includes a significantly lower dose (orders of magnitude) and higher tissue specificity, potentially mitigating inflammation risks associated with high-dose vectors.
• Competition includes first-generation anti-VEGFs, longer-acting agents (e.g., Bimso/BIO), biosimilars, and TK inhibitors, all of which generally offer incremental durability gains rather than "continuous control."

Risks and Challenges:

• Safety risks associated with gene therapies, specifically inflammation, though management cites the R100 vector's specificity and the prophylactic steroid regimen as mitigating factors.
• Potential physician economic concerns regarding revenue loss from reduced injection frequency; management argues the higher unit price, capture of lost patients, and relief of clinic capacity constraints offset this.
• Regulatory uncertainty regarding retreatment criteria and rescue protocols within the trial design, though FDA interactions have been supportive.
• Execution risk associated with achieving the stringent non-inferiority vision endpoints in the Phase 3 trials.

Management Commentary and Tone:

• Tone is highly confident and optimistic, emphasizing a "paradigm shift" from episodic bolus treatment to continuous backbone therapy.
• Management stresses that the approach aligns with the chronic biology of wet AMD, solving the "continuous control gap" where current therapies fail to maintain vision long-term.
• Chris Sims (CCO/Business Officer) expressed surprise at the lack of patient/physician hesitation regarding the 20-week steroid regimen, citing overwhelming patient interest in the potential for lifelong freedom from injections.
• The team highlighted the "unmet need" as a primary driver for rapid Phase 3 enrollment (completed within 12 months) and enthusiastic support from the clinical community.

Analyst Questions and Answers:

• Q: How does trial design increase probability of success? A: Focusing on treatment-naive patients (aligning with FDA guidance for vision benefit), strict anatomical entry criteria (capping CST at 500 microns, requiring fluid resolution), and rescue criteria designed to prioritize vision protection over burden reduction.
• Q: What are expectations for retreatment/rescue rates? A: Management declined to give a specific number to avoid binary investor expectations but indicated historical PRISM data showed 80-90% burden reduction in recently diagnosed cohorts and 40-60% treatment-free rates. They anticipate results will be "highly relevant" and potentially paradigm-shifting.
• Q: How does this compare to competing gene therapies? A: 4D-150 avoids the surgical requirement of subretinal approaches and the high-dose inflammation risks of other intravitreal vectors, positioning it for seamless clinic integration.
• Q: Will reduced injections hurt physician revenue? A: Management argues the buy-and-bill model with a higher single-dose price, combined with capturing patients lost to discontinuation and alleviating clinic capacity issues, creates a superior economic model for clinics compared to the current standard.

Other Key Points:

• Regulatory designations include RMAD (FDA) and PRIME (EMA), with productive interactions also noted with PMDA.
• The trial design allows for supplemental treatment if vision is threatened, but this is strictly regulated to ensure the primary endpoint (vision non-inferiority) is met first.
• The product is designed to be a single in-office intravitreal injection, fitting directly into existing retina clinic workflows without requiring operating room time.